Submitted by Bryan DeSouza, MD
COVID-19 and Neuromuscular Disorders
Amanda C. Guidon, MD, and Anthony A. Amato, MD Neurology® 2020;94:959-969. doi:10.1212/WNL.0000000000009566
Note From the Editor:
The goal of the AANEM News Science editorial members and staff are to keep it members informed about the latest scientific knowledge, developments and breakthroughs in neuromuscular diseases. Starting with this issue my colleagues and I will be highlighting important information as it relates, to COVID-19 and neuromuscular diseases. We will continue to provide our members with best practices information for electromyographers and neuromuscular clinicians to help them achieve the best care for our patients. For this reason, I would encourage all our members to read the practice guidelines at www.aanem.org/Practice/COVID-19-Guidance
. Working together we will overcome this pandemic.
Drs. Guidon and Amato provide a timely review of the COVID-19 pandemic's potential effects on patients with neuromuscular disorders. They cover the broad spectrum of how the pandemic affected the delivery of neuromuscular care to education and research. This article reviews potential neuromuscular complications of COVID-19, assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, guidance for management of immunosuppressive and immunomodulatory therapies, practical guidance in neuromuscular care, telemedicine, education, and its effect on neuromuscular research.
Comments: This article provides a methodical approach to the evaluation and management of our patients with guidance in immunosuppressive and immunomodulatory therapies. It strongly emphasizes the need for a team-based and multidisciplinary collaboration for care.